Moderna's stock price jumped early Thursday as the biotech firm drew one step closer to revealing how well its experimental coronavirus vaccine works.
Biotech firm Moderna expects to have about 20 million doses of its experimental coronavirus vaccine ready to ship in the US by the end of the year.
The Massachusetts-based drug developer will be
Shares of German biotechnology firm CureVac nearly tripled in their Nasdaq debut Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus. The stock opened at $44 per share, up from the initial public offering price of $16 per share. CureVac, backed by Microsoft founder and …